Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 9032 results

  1. MT633 FreeO2 Automatic Oxygen Titration

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  2. Riluzole oral film for treating amyotrophic lateral sclerosis [TSID11779]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 [TSID11778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. VER-01 for treating chronic low back pain [ID6638]

    Awaiting development Reference number: GID-TA11842 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

    Awaiting development Reference number: GID-TA10486 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Zavegepant for treating acute migraine [TSID11998]

    Awaiting development Reference number: GID-TA11527 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Edaravone for treating amyotrophic lateral sclerosis [TSID11869]

    Awaiting development Reference number: GID-TA11362 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Acne

    Awaiting development Reference number: GID-QS10036 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]

    Awaiting development Reference number: GID-TA10519 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development Reference number: GID-TA10553 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

    HealthTech guidance
    Awaiting development